Showing results (2621-2630 of 2,696) with videos related to

Sort By:
Pageof 270
The Lancet. Infectious Diseases|November 1, 2025
Oral itraconazole versus oral voriconazole for treatment-naive patients with chronic pulmonary aspergillosis in India (VICTOR-CPA trial): a single-centre, open-label, randomised, controlled, superiority trialInderpaul Singh Sehgal, Ritesh Agarwal, Sahajal Dhooria, et al.
The Lancet. Infectious Diseases|November 1, 2025
Safe delivery of intensive care for Marburg virus disease in RwandaEric Seruyange, Ernest Nahayo, François Xavier Uwimana, et al.
The Lancet. Infectious Diseases|June 22, 2025
First human infection and management of Versteria rafei infection restricted to the liver with phylogenetic analysis in the context of known casesJonas Buttenschoen, Kinga Kowalewska-Grochowska, David Kleinman, et al.
The Lancet. Infectious Diseases|September 26, 2025
Human monoclonal antibody MAM01 for protection against malaria in adults in the USA: a first-in-human, phase 1, dose-escalation, double-blind, placebo-controlled, adaptive trialKirsten E Lyke, Andrea A Berry, Matthew B Laurens, et al.
The Lancet. Infectious Diseases|May 15, 2025
Effectiveness of integrated vector management on the incidence of dengue in urban Malaysia: a cluster-randomised controlled trialMitra Saadatian-Elahi, Muriel Rabilloud, Tim W R Möhlmann, et al.
The Lancet. Infectious Diseases|May 25, 2025
Efficacy and safety of 8-week regimens for the treatment of rifampicin-susceptible pulmonary tuberculosis (TRUNCATE-TB): a prespecified exploratory analysis of a multi-arm, multi-stage, open-label, randomised controlled trialNicholas I Paton, Christopher Cousins, Intan P Sari, et al.
The Lancet. Infectious Diseases|July 17, 2025
Extended nirmatrelvir-ritonavir treatment durations for immunocompromised patients with COVID-19 (EPIC-IC): a placebo-controlled, randomised, double-blind, phase 2 trialEdward Weinstein, Roger Paredes, Annie Gardner, et al.
The Lancet. Infectious Diseases|July 11, 2025
Delpazolid in combination with bedaquiline, delamanid, and moxifloxacin for pulmonary tuberculosis (PanACEA-DECODE-01): a prospective, randomised, open-label, phase 2b, dose-finding trialLilian Tina Minja, Isabella van der Feltz, Christina Manyama, et al.
The Lancet. Infectious Diseases|May 9, 2025
Moxidectin combination therapies for lymphatic filariasis: an open-label, observer-masked, randomised controlled trialGuibehi Benjamin Koudou, Catherine M Bjerum, Foungoye Allassane Ouattara, et al.
The Lancet. Infectious Diseases|October 9, 2025
Cefiderocol versus standard therapy for hospital-acquired and health-care-associated Gram-negative bacterial bloodstream infection (the GAME CHANGER trial): an open-label, parallel-group, randomised trialDavid L Paterson, Helmi Sulaiman, Po-Yu Liu, et al.
Pageof 270